Extracorporeal membrane oxygenation
(ECMO) is used in critical
care to manage patients with severe respiratory and cardiac failure.
ECMO brings blood from a critically ill patient into contact with
a non-endothelialized circuit which can cause clotting and bleeding
simultaneously in this population. Continuous systemic anticoagulation
is needed during ECMO. The membrane oxygenator, which is a critical
component of the extracorporeal circuit, is prone to significant thrombus
formation due to its large surface area and areas of low, turbulent,
and stagnant flow. Various surface coatings, including but not limited
to heparin, albumin, poly(ethylene glycol), phosphorylcholine, and
poly(2-methoxyethyl acrylate), have been developed to reduce thrombus
formation during ECMO. The present work provides an up-to-date overview
of anti-thrombogenic surface coatings for ECMO, including both commercial
coatings and those under development. The focus is placed on the coatings
being developed for oxygenators. Overall, zwitterionic polymer coatings,
nitric oxide (NO)-releasing coatings, and lubricant-infused coatings
have attracted more attention than other coatings and showed some
improvement in in vitro and in vivo anti-thrombogenic effects. However, most studies lacked standard
hemocompatibility assessment and comparison studies with current clinically
used coatings, either heparin coatings or nonheparin coatings. Moreover,
this review identifies that further investigation on the thrombo-resistance,
stability and durability of coatings under rated flow conditions and
the effects of coatings on the function of oxygenators (pressure drop
and gas transfer) are needed. Therefore, extensive further development
is required before these new coatings can be used in the clinic.